GW&K Investment Management LLC reduced its position in Alkermes Plc (NASDAQ:ALKS) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 306,678 shares of the company’s stock after selling 1,853 shares during the quarter. GW&K Investment Management LLC owned about 0.20% of Alkermes worth $16,784,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of ALKS. Prudential Financial Inc. raised its position in shares of Alkermes by 5.0% in the 2nd quarter. Prudential Financial Inc. now owns 9,095 shares of the company’s stock worth $527,000 after buying an additional 430 shares during the period. JPMorgan Chase & Co. raised its position in shares of Alkermes by 950.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 47,526 shares of the company’s stock worth $2,756,000 after buying an additional 43,000 shares during the period. Wells Fargo & Company MN raised its position in shares of Alkermes by 4.9% in the 2nd quarter. Wells Fargo & Company MN now owns 297,750 shares of the company’s stock worth $17,260,000 after buying an additional 13,923 shares during the period. Alliancebernstein L.P. raised its position in shares of Alkermes by 1.3% in the 2nd quarter. Alliancebernstein L.P. now owns 98,140 shares of the company’s stock worth $5,689,000 after buying an additional 1,275 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Alkermes by 8.8% in the 2nd quarter. Teachers Advisors LLC now owns 169,027 shares of the company’s stock worth $9,798,000 after buying an additional 13,716 shares during the period. 99.20% of the stock is currently owned by institutional investors and hedge funds.
Alkermes Plc (NASDAQ:ALKS) opened at $57.03 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. Alkermes Plc has a 52-week low of $46.42 and a 52-week high of $63.40. The company has a market capitalization of $8,769.84, a PE ratio of -51.38 and a beta of 2.13.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm’s revenue was up 20.6% compared to the same quarter last year. During the same period last year, the company posted ($0.09) earnings per share. equities research analysts anticipate that Alkermes Plc will post -0.59 EPS for the current fiscal year.
ALKS has been the topic of several research reports. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Monday, January 8th. Mizuho set a $81.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Saturday, October 21st. Credit Suisse Group set a $66.00 price objective on Alkermes and gave the company a “buy” rating in a research report on Tuesday, November 28th. ValuEngine lowered Alkermes from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, UBS Group set a $54.00 price objective on Alkermes and gave the company a “hold” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $63.33.
In other news, SVP Michael J. Landine sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the sale, the senior vice president now directly owns 178,693 shares in the company, valued at $8,704,136.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $51.98, for a total value of $51,980.00. Following the sale, the director now owns 9,000 shares of the company’s stock, valued at $467,820. The disclosure for this sale can be found here. Insiders have sold 142,624 shares of company stock valued at $7,633,176 over the last 90 days. Insiders own 5.34% of the company’s stock.
WARNING: “GW&K Investment Management LLC Cuts Position in Alkermes Plc (ALKS)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/22/gwk-investment-management-llc-cuts-position-in-alkermes-plc-alks.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.